These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 27878567)

  • 1. Drug Interactions Between Peficitinib, an Orally Administered, Once-Daily Janus Kinase Inhibitor, and Rosuvastatin in Healthy Subjects.
    Zhu T; Parker B; Wojtkowski T; Nishimura T; Garg JP; Han D; Fisniku O; Keirns J
    Clin Pharmacokinet; 2017 Jul; 56(7):747-757. PubMed ID: 27878567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Verapamil, a P-Glycoprotein Inhibitor, on the Pharmacokinetics of Peficitinib, an Orally Administered, Once-Daily JAK Inhibitor.
    Zhu T; Howieson C; Wojtkowski T; Garg JP; Han D; Fisniku O; Keirns J
    Clin Pharmacol Drug Dev; 2017 Nov; 6(6):548-555. PubMed ID: 28301084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
    Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
    Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A drug-drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers.
    Shibata M; Toyoshima J; Kaneko Y; Oda K; Nishimura T
    Eur J Clin Pharmacol; 2020 Aug; 76(8):1135-1141. PubMed ID: 32472157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.
    Allred AJ; Bowen CJ; Park JW; Peng B; Williams DD; Wire MB; Lee E
    Br J Clin Pharmacol; 2011 Aug; 72(2):321-9. PubMed ID: 21434975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, Pharmacodynamics, and Safety of ASP015K (Peficitinib), a New Janus Kinase Inhibitor, in Healthy Subjects.
    Cao YJ; Sawamoto T; Valluri U; Cho K; Lewand M; Swan S; Lasseter K; Matson M; Holman J; Keirns J; Zhu T
    Clin Pharmacol Drug Dev; 2016 Nov; 5(6):435-449. PubMed ID: 27162173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects.
    Mohamed MF; Coppola S; Feng T; Camp HS; Kim E; Othman AA
    Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1335-1344. PubMed ID: 34109764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Safety of Single and Multiple Doses of Peficitinib (ASP015K) in Healthy Chinese Subjects.
    Gao X; He X; Oshima H; Miyatake D; Otsuka Y; Kato K; Cai C; Wojtkowski T; Song N; Kaneko Y; Shi A
    Drug Des Devel Ther; 2022; 16():1365-1381. PubMed ID: 35586186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function.
    Miyatake D; Shibata T; Toyoshima J; Kaneko Y; Oda K; Nishimura T; Katashima M; Sakaki M; Inoue K; Ito T; Uchida N; Furihata K; Urae A
    Clin Pharmacol Drug Dev; 2020 Aug; 9(6):699-708. PubMed ID: 31833184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects with Normal and Impaired Renal Function.
    Miyatake D; Shibata T; Shibata M; Kaneko Y; Oda K; Nishimura T; Katashima M; Sekino H; Furihata K; Urae A
    Clin Drug Investig; 2020 Feb; 40(2):149-159. PubMed ID: 31729626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transporters.
    Gidal BE; Mintzer S; Schwab M; Schutz R; Kharidia J; Blum D; Grinnell T; Sunkaraneni S
    Epilepsy Res; 2017 Sep; 135():64-70. PubMed ID: 28624574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
    Takeuchi T; Tanaka Y; Tanaka S; Kawakami A; Song YW; Chen YH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Nakashima Y; Shiomi T; Yamada E
    Arthritis Res Ther; 2020 Mar; 22(1):47. PubMed ID: 32164762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Bioequivalence of Two Peficitinib Formulations, and the Effect of Food on the Pharmacokinetics of Peficitinib: Two-Way Crossover Studies of a Single Dose of 150 mg Peficitinib in Healthy Volunteers.
    Shibata M; Toyoshima J; Kaneko Y; Oda K; Kiyota T; Kambayashi A; Nishimura T
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):283-290. PubMed ID: 32618438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic interaction between rosuvastatin and olmesartan: a randomized, open-label, 3-period, multiple-dose crossover study in healthy Korean male subjects.
    Roh H; Son H; Lee D; Chang H; Yun C; Park K
    Clin Ther; 2014 Aug; 36(8):1159-70. PubMed ID: 25017182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
    Tanaka Y; Takeuchi T; Tanaka S; Kawakami A; Iwasaki M; Song YW; Chen YH; Wei JC; Lee SH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Akazawa R; Shiomi T; Yamada E
    Ann Rheum Dis; 2019 Oct; 78(10):1320-1332. PubMed ID: 31350270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, Pharmacodynamics, and Safety of Peficitinib (ASP015K) in Healthy Male Caucasian and Japanese Subjects.
    Shibata M; Hatta T; Saito M; Toyoshima J; Kaneko Y; Oda K; Nishimura T
    Clin Drug Investig; 2020 May; 40(5):469-484. PubMed ID: 32274653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic interaction between rosuvastatin and metformin in healthy Korean male volunteers: a randomized, open-label, 3-period, crossover, multiple-dose study.
    Lee D; Roh H; Son H; Jang SB; Lee S; Nam SY; Park K
    Clin Ther; 2014 Aug; 36(8):1171-81. PubMed ID: 24976448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis.
    Qiu Q; Feng Q; Tan X; Guo M
    Expert Rev Clin Pharmacol; 2019 Jun; 12(6):547-554. PubMed ID: 31059310
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of Steady-State Faldaprevir on Pharmacokinetics of Atorvastatin or Rosuvastatin in Healthy Volunteers: A Prospective Open-Label, Fixed-Sequence Crossover Study.
    Huang F; Marzin K; Koenen R; Kammerer KP; Strelkowa N; Elgadi M; Quinson AM; Haertter S
    J Clin Pharmacol; 2017 Oct; 57(10):1305-1314. PubMed ID: 28513969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
    Elsby R; Martin P; Surry D; Sharma P; Fenner K
    Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.